

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁵: A61K 47/48</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/13322 (43) International Publication Date: 23 June 1994 (23.06.94)</p>
<p>(21) International Application Number: PCT/EP93/03429 (22) International Filing Date: 6 December 1993 (06.12.93) (30) Priority Data: 9225448.1 4 December 1992 (04.12.92) GB (71) Applicant (for all designated States except US): FARMITALIA CARLO ERBA S.R.L. [IT/IT]; Via Carlo Imbonati, 24, I- 20159 Milan (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): MARCUCCI, Fabrizio [IT/IT]; Piazza del Carroccio, 23, I-20025 Legnano (IT). GREGORY, Ruth [GB/IT]; Viale Vittorio Veneto, 12, I- 20124 Milan (IT). (74) Agents: WOODS, Geoffrey, Corlett et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).</p>		<p>(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: IMPROVED SYNTHESIS OF POLYMER BIO-ACTIVE CONJUGATES</p> <p>(57) Abstract</p> <p>A process for the preparation of a conjugate between a polymer and a first substance having a biological activity mediated by a domain thereof, which process comprises: (a) contacting the first substance with a second substance which specifically binds to the said domain of the first substance (b); conjugating a polymer to the first substance having the second substance bound thereof; and (c) freeing the second substance from the first substance having the polymer conjugated thereto. Conjugates between a polymer and an antibody against TNF-α.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

IMPROVED SYNTHESIS OF POLYMER BIO-ACTIVE CONJUGATES

The present invention relates to a process for the preparation of a conjugate between a polymer and a bioactive substance.

5 In the last decade a steadily increasing number of proteins have entered routine clinical use as therapeutic or diagnostic agents (see, for example, Waldmann, T.A., Science, 252 : 1657-1662, 1991 and Jaffe, H.S. and Sherwin, S.A., Drugs of Today, 25 : 311-320, 1989 and Foon, K.A., Cancer
10 Research, 49 : 1621-1639, 1989). The efficacy of many of these agents, however, is limited for two main reasons.

First, the in vivo half-life is often very short (see, for example, Mühlradt, P.F. and Opitz, H.G., European Journal of Immunology, 12 : 983-985, 1982 and Jacobs, C.A.,
15 Lynch, D.H., Roux, E.R., Miller, R., Davis, B., Widmer, M.B., Wignall, J., VandenBos, T., Park, L.S. and Beeckmann, M.P., Blood, 77 : 2396-2403, 1991 and Blick, M., Sherwin, S.A., Rosenblum, M. and Gutterman, J., Cancer Research, 47 : 2986-
2989, 1987).

20 Second, in case of heterologous proteins, another problem adds to the first. This is due to the proteins being recognized as foreign substances (antigens) by the immune system of the species treated, thereby leading to an immune response that abolishes, upon a second administration, the
25 pharmacological activity of the heterologous protein (see, for example, Shawler, D.L., Bartholomew, R.M., Smith, L.M. and Dillman, R.O., Journal of Immunology, 135: 1530-1535, 1985 and Schroff, R.W., Foon, K.A., Beatty, S.M., Oldham,

- 2 -

R.K. and Morgan, A.C., Cancer Research, 45 : 879-885, 1985 and Traub, U.C., De Jager, R.L., Primus, F.J., Losman, M. and Goldenberg, D.M., Cancer Research, 48 : 4002-4006, 1988).

For these reasons methods have been sought to
5 overcome either one or both of the above mentioned problems, i.e. to prolong the in vivo half-life of proteins and to reduce their antigenicity in case of proteins heterologous with respect to the species to be treated. One particular approach that has been taken is to conjugate proteins to
10 soluble synthetic polymers, in particular poly(ethylene glycol), poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(amino acids), divinylether maleic anhydride, ethylene-maleic anhydride, N-(2-hydroxypropyl)methacrylamide and dextran (see, for example, Abuchowski, A., Van Es, T.,
15 Palczuk, N.C. and Davis, F.F. Journal of Biological Chemistry 11, 3578-3581, 1977; Yasuda, Y., Fujita, T., Takakura, Y., Hashida, M., and Sezaki, H. Chemistry and Pharmaceutical Bulletin 38, 2053-2056, 1990; Fagnani, R., Hagan, M.S. and Bartholomew, Cancer Research 50, 3638-3645 (1990); Suck, J.M.
20 and Wild, B.S. US-A-3679653, 1972; Flanagan, P.A., Duncan, R., Rihova, B., Subr, V. and Kopecek, J., Journal of Bioactive and Compatible Polymers 5, 151-166, 1990.

More than 40 proteins have now been modified, mainly using poly(ethylene glycol), but it has been
25 shown that a variety of other polymers can be substituted to provide reduced immunogenicity and protein stabilisation. In particular, the approach has been used to modify enzymes including arginase, asparaginase, adenosine deaminase

- 3 -

galactosidase, lipase, pro-urokinase, streptokinase, superoxide dismutase, trypsin and uricase (see, for example, Nucci, M.L., Shorr, R. and Abuchowski, A. Advanced Drug Delivery Reviews 6, 133-151, 1991; Veronese, F.M., Caliceti, P., Pastorino A., Schiavon, O., and Sartore. Journal of Controlled Release 10, 145-154, 1989); cytokines and growth factors such as interleukin 2 and human granulocyte colony-stimulating factor (see, for example, Katre, N.V. Journal of Biological Chemistry 144, 209-213, 1990; Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S. and Asano, K. Cancer Research 51, 3710-3714, 1991) and antibodies (see, for example, Kitamura, K., Takahashi, T., Yamaguchi, T., Noguchi, A., Takashina, K., Tsurumi, H., Inagake, M., Toyokuni, T. and Hakomori, S. Cancer Research 51, 4310-4315, 1991).

15 A number of methods have been described for linkage of polymers to bio-active protein molecules (see, for example, US-A-4179337, US-A-4732863, Jackson C.-J., Charlton, J.L., Kuzminski, K., Lang, G.M. and Sehon A.H. Analytical Biochemistry 165, 114-127, 1987; Veronese, F., M., Largaajolli, R., Boccu, E., Benassi, C.A. and Schiavon, O. Applied Biochemistry and Biotechnology 11, 141-152, 1985 ; W093/15189).

However, the methods currently available for conjugation have two major drawbacks. Usually, other than the Veronese approach
25 in W093/15189, first, the derivatisation procedures reported are inherently random thereby leading to the introduction of polymeric moieties into domains of the molecule that mediate

- 4 -

the therapeutically or diagnostically desirable activity(ies). Consequently, the molecule may acquire a prolonged half-life in vivo and, in case of heterologous proteins, reduced immunogenicity, but at the expense of a significant or complete loss
5 of the desired biological activity(ies) (see, for example, Kitamura, K., Takahashi, T., Yamaguchi, T., Noguchi, A., Noguchi, A., Takashima, K.-i., Tsurumi, H., Inagake, M., Toyokuni, T. and Hakanori, S.-i., Cancer Research, 51 : 4310-4315, 1991 and Maiti, P.K., Lang, G.M. and Sehon, A.H., International
10 Journal of Cancer, Supplement 3: 17-22, 1988).

Loss of biological activity following polymer conjugation has been observed in the case of both antibodies and enzymes, particularly when access of the modified protein to a macromolecular substrate or receptor is essential to
15 produce biological activity. However, it has been found that inactivation of enzymatic activity is not necessarily a result of polymer conjugation if the domain(s) mediating activity either do not contain functional groups suitable for polymer derivatisation, and/or the binding of polymer
20 molecule(s) does not sterically hinder access of low molecular weight enzyme substrates.

In fact, enzymes like adenosine deaminase and L-asparaginase have been successfully conjugated with polyethylene glycol (see, for example, Hershfield, M.S.,
25 Buckley, R.H., Greenberg, M.L., Melton, A.L., Schiff, R., Hatem, C., Kurtzberg, J., Markert, M.L., Kobayashi, R.H., Kobayashi, A.L. and Abuchowski, A., The New England Journal of Medicine, 316 : 589-596, 1987 and Teske, E., Rutteman, G.R., van Heerde, P. and Misdorp, W., European Journal of
30 Cancer, 26 : 891-895, 1990). In one case (adenosine

- 5 -

deaminase) the product thereby obtained has received approval for clinical use in humans. These examples, however, are the exception rather than the rule.

A second problem associated with synthesis of
5 polymer-protein conjugates has been heterogeneity of the product formed. Polymers are by nature heterogeneous, displaying within any sample a range of molecular weights, ie. they are polydisperse, and in addition any preparation also displays a heterogeneity in the number of functional
10 groups available for attachment to the protein to be modified. Thus, during the conjugation reaction there is opportunity to form a multitude of products. This problem has been previously been exacerbated by the need to control carefully the degree of protein modification to a minimum to
15 ensure retention of substantial biological activity of the protein, whilst concurrently introducing a sufficient number of polymer molecules into the conjugate to facilitate the needed reduction in immunogenicity, and protein stabilisation.

20 According to the present invention, there is provided a process for the preparation of a conjugate between a polymer and a first substance having a biological activity mediated by a domain thereof, which process comprises:

(a) contacting the first substance with a second
25 substance which specifically binds to the said domain of the first substance;

(b) conjugating a polymer to the first substance having the second substance bound thereto; and

- 6 -

(c) freeing the second substance from the first substance having the polymer conjugated thereto, and wherein, when the first substance is a proteolytic enzyme chosen from trypsin, urokinase, tissue plasminogen activator, plasmin, 5 chymotrypsin, elastase and kallikrein then the polymer is other than polyethylen glycol.

A significant improvement can thus be achieved. The procedure of the invention preserves the advantages deriving from the conjugation of polymers to therapeutically 10 or diagnostically useful molecules, i.e. prolonged half-life in vivo and reduced immunogenicity in case of heterologous proteins. Further, a desired biological activity is not lost and a homogeneous product can be attained.

The invention relies upon the use of a second 15 substance that specifically recognizes a domain that mediates the desired biological activity of a first substance which is to be derivatized. The second substance can be viewed as a specific binder substance. The first substance is allowed to interact with the specific binder before effecting polymer 20 conjugation. This ensures that the domain of the first substance that mediates the desired biological activity of that substance is shielded and consequently unavailable for derivatization by the polymer. Following its elution from the specific binder, the conjugate between the polymer and 25 the first substance can be recovered with fully preserved biological activity.

The first substance may be any molecule having a desired activity. The substance may be a physiologically active substance. The first substance is typically an

- 7 -

organic macromolecular entity such as a protein or a glycoprotein. The second substance binds to a site on the first substance which mediates the activity of the first substance. The second substance therefore protects the active site of the first substance.

The invention may be applied broadly. The first substance may be an antibody or antibody fragment, cytokine, antigen, enzyme, ligand or receptor. The second substance may be, respectively, an antigen or antidiotypic antibody, receptor or anticytokine antibody, antibody, enzyme substrate, receptor or ligand. In each case the second substance specifically binds to the first substance to shield the domain of the first substance which is responsible for the activity of the first substance. Examples of pairs of first and second substances are as follows.

1. When the first substance is a monoclonal antibody (mAb), including anti-idiotypic and anti-anti-idiotypic antibodies, or mAb fragment such as Fab' and F(ab)₂ fragments, the second substance may be the antigen to which the mAb or mAb fragment binds or an antibody including idiotypic, anti-idiotypic, anti-anti-idiotypic antibodies. The mAb or mAb fragment which constitutes the first substance may be specific for any appropriate antigen, for example human tumor necrosis factor α (hu TNF α). The mAb fragment may be non-human, for example a murine mAb or mAb fragment.

2. The first substance may be a protein and the second substance may be a ligand which specifically binds to an

- 8 -

active site of the protein. The first substance may be a fibrinolytic enzyme such as pro-urokinase (pro-UK), urokinase (UK) or tissue plasminogen activator (tPa) or a fibrinolytic agent such as streptokinase or a non-protease enzyme, such as β -glucuronidase, purine nucleoside phosphorylase, bilirubin oxidase or superoxide dismutase. The second substance may be a mAb which is directed against the specific active site of the first substance. Alternatively the second substance may be the ligand with which the first substance normally interacts.

10 For example:

- First substance: streptokinase or hirudin, second substance plasminogen or thrombin respectively; and
- first substance: a growth factor such as FGF, EGF, PDGF, HGH or HGF, a growth factor receptor, a lymphokine or cytokine such as an inteteron, interleukin, stimulating factor, TNF α or TNF β or a lymphokine or cytokine receptor; second substance the correponding growth factor receptor, the corresonding growth factor, the corresponding lymphokine or cytokine receptor or the corresponding lymphokine or cytokine respectively.

The second substance may be a low molecular weight ligand. This applies generally to all therapeutic proteins having enzymic activity and to proteolytic enzymes. The therapeutic protein may be a fibrinolytic enzyme such as pro-UK, UK or tPA and the second substance may be benzamidine or a derivative thereof. A heparin-binding protein, for example a growth factor such as FGF or HGF, may be the first substance and heparin or a heparin-like molecule or a heparin derivative typically having a low molecular weight and a negative charge may constitute the second substance.

- 9 -

In other instances, the first substance may be a protein that interacts with a peptide ligand. This may be applied to any protein having a therapeutic application. The first substance may be a DNA binding protein and the second substance may be DNA or an oligonucleotide.

In some instances it may be desirable to preserve the biological activities mediated by two separate domains of the first substance. In such cases both biological activities can be preserved through the use of two specific binders each one recognizing one of the two biologically active domains. Thus, for example, monoclonal antibodies against tumor-associated antigens destroy the relevant target cells through binding on the one hand, to the antigen with their variable regions and, on the other hand, to killer cells (K cells) through their constant regions. The K cells become at this point the actual effector of the lytic process that leads to the destruction of the tumorigenic target cell. This process is called antibody-dependent cellular cytotoxicity.

In this case it would be desirable to preserve binding of the monoclonal antibody to both cell types (tumor cell and K cell). This can be achieved, according to the present invention, by performing the conjugation step after having shielded, on the one hand, the antigen-binding regions with the tumor-associated antigen and, on the other hand, the binding site for K cells with the K cell-receptor for the constant region of the monoclonal antibody.

The first substance's active domain is therefore protected by the second substance. The first substance can then be conjugated to a polymer. Generally the polymer is an inert, synthetic, polymeric carrier. The polymer is usually water-soluble.

- 10 -

The polymer may be poly(ethylene glycol) (PEG), poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(amino acids), divinylether maleic anhydride, ethylene-maleic anhydride, N-(2-hydroxypropyl)-methacrylamide or dextran.

5 The polymer may be derivatised or activated itself prior to use. PEGylation may be achieved using, for example, monomethoxypolyethyleneglycol-succinimidyl succinate (mPEG). Coupling may be effected using techniques analogous to those already known in the art, for example according to US-A-10 4179337, US-A-4732863, WO 91/01758, WO 91/15242, US-A-4935465 and US-A-4415665.

Generally there is a molar excess of polymer with respect to the first substance. In accordance with the present invention the molar excess may be from 1 to 500 15 times, or higher, without there being any loss of function activity. Conjugation must be carried out under such conditions that the second substance does not disassociate from the first substance during the binding procedure. When the first substance is an antibody and the second substance 20 is an antiidiotypic antibody, therefore, the pH of the reaction medium is about 7, typically from about 6.3 to about 7.8, in particular about 7.2. Preferably conjugation is effected under conditions such that polymer is conjugated to the first substance at substitution levels for the reduction 25 of immunogenic activity or elongation of the half-life of the biologically active substance. The person skilled in the art will appreciate that many other polymers can be used for this purpose. In a preferred embodiment, the specific binder that affords protection during the polymer conjugation step is

- 11 -

first covalently linked to a solid phase such as column packing materials, for instance sephadex or agarose beads, or a surface, e.g. reaction vessel. This allows the polymer-derivatized first molecule to be separated from the specific binder by elution. The fluid phase containing the derivatized first substance is separated from the solid phase to which the specific binder remains covalently-linked. Such separation can be achieved by many other means. Thus, the specific binder may be derivatised itself with a third molecule (e.g. biotin) that can itself be recognized by a second specific binder (e.g. streptavidin). The second specific binder may be linked to a solid phase thereby allowing the separation of the polymer-derivatized first molecule from the first specific binder-third molecule complex through passage over a second specific binder-solid phase column which will retain, upon subsequent elution, the first specific binder-third molecule complex, but not the polymer-derivatized first molecule. The first substance to which the polymer is conjugated may be released from the second substance in any appropriate fashion. Deprotection may be achieved by providing conditions in which the second substance dissociates from the active domain of the first substance. A complex between an antibody to which a polymer is conjugated and an antiidiotypic antibody can be dissociated by adjusting the pH to an acid or alkaline pH.

The following Examples illustrate the invention.

- 12 -

In the accompanying drawings:

5 Figure 1 shows the cytotoxic activity on LM cells of 1 ng/ml huTNF α in the presence of increasing concentrations of mAb78. The x-axis denotes the concentration of mAb78 in ng/ml. The y-axis denotes the percentage viability of LM cells in the presence of 1 ng/ml huTNF α and different concentrations of mAb78. The Figure indicates the concentration of mAb78 at which 1 ng/ml

10 huTNF α exerts 50% cytotoxic activity (6.7 ng/ml).

Figure 2 shows the concentrations in ng/ml of mAb78 or unprotected mAb78-mPEG conjugates at which 1 ng/ml huTNF α exerts 50% cytotoxic activity on LM cells (y-axis). (1) mAb78; (2) unprotected mAb78

15 derivatized upon addition of a 3-fold molar excess of mPEG (mAb78+mPEG 3x); (3) mAb78 + mPEG 15x (4) mAb78 + mPEG 62.5x; (5) mAb78 + mPEG 125x; (6) mAb78 + mPEG 250x; (7) mAb78 + mPEG 300x; (8) mAb78 + mPEG 500x.

20 Figure 3 shows the concentrations in ng/ml of mAb78, unprotected mAb78-mPEG or protected mAb78-mPEG conjugates at which 1 ng/ml huTNF α exerts 50% cytotoxic activity on LM cells (y-axis). (1) mock-derivatized mAb78; (3) unprotected mAb78

25 derivatized upon addition of a 15-fold molar excess of mPEG (calculated on the mAb78 concentration); (2) protected mAb78 derivatized

- 13 -

upon addition of a 15-fold molar excess of mPEG
 (calculated on the concentration of mAb78+mAb2);
 (5) unprotected mAb78 + mPEG 100x; (6)
 unprotected mAb78 and mouse IgG derivatized upon
 5 addition of a 100-fold molar excess of mPEG
 (calculated on the mAb78 + mouse IgG
 concentrations); (4) protected mAb78 + mPEG 100x;
 (7) as (1); (8) as (4); (9) as (5); (10) as (1);
 (12) unprotected mAb78 + mPEG 500x; (11)
 10 protected mAb78 + mPEG 500x.

Figure 4 shows the detection of mAb78, unprotected mAb78-
 mPEG or protected mAb78-mPEG conjugates in a
 mouse IgG-specific ELISA. A : (●) mock-
 derivatized mAb78; (Δ) unprotected mAb78
 15 derivatized upon addition of a 100-fold molar
 excess of mPEG (unprotected mAb78 + mPEG 100x);
 (○) protected mAb78 derivatized upon addition of
 a 100-fold molar excess of mPEG. B : (●) mock-
 derivatized mAb 78; (Δ) unprotected mAb78 + mPEG
 20 500x; (○) protected mAb78 + mPEG 500x. x-axis:
 concentration of mAb78 in ng/ml. y-axis: O.D.
 units.

Figure 5 shows the inhibition of the binding of ¹²⁵I-huTNFα
 to recombinant TNF-R1 receptor by unprotected
 25 huTNFα-mPEG or huTNFα-mPEG protected with
 insolubilized anti-huTNFα mAb78. y-axis: amount
 of competitor in μg. ■ denotes huTNFα, ▤
 denotes huTNFα-PEG30x and ▥ denotes protected
 huTNFα-PEG30x.

- 14 -

A further object of the present invention is to provide a conjugate between a polymer and an anti-tumor necrosis factor α antibody preferably a monoclonal antibody against human TNF α .

- 5 The polymer is generally an inert, synthetic, polymeric carrier. The polymer is usually water soluble. Preferred examples of polymers according to the invention are poly(ethylene glycol) (PEG), poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(amino acids), divinylether maleic
10 anhydride, ethylene-maleic anhydride, N-(2-hydroxypropyl)-methacrylamide or dextran.

The monoclonal antibody against TNF may be either a human or non-human antibody, typically mAb78 as disclosed in EP-A-0492488.

- 15 The conjugates between a polymer and a monoclonal antibody against TNF according to the invention can be administered to mammals, comprising humans, according to the diseases and administration routes well known to the people skilled in the art.
- 20 The conjugates between a polymer and anti-tumor necrosis factor- α antibody of the present invention can be employed in mammals, including humans, for prophylactic and/or therapeutic use in any disease state in which TNF α and/or TNF β are known to exert a pathogenic effect. Typically such
25 disease states are cachexia, septic shock, graft-versus-host disease, AIDS, cerebral malaria, rheumatoid arthritis, chronic and acute inflammatory diseases, myocardial ischaemia

- 15 -

and others in which it is already known or will be known in the future that $\text{TNF}\alpha$ and/or $\text{TNF}\beta$ play a detrimental role. For instance doses ranging from about 0.5 to about 20 mg/kg of body weight can be used for parenteral administration in adult humans, e.g. in treating septic shock for adduct PEG-mAb78. Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide an antibody quantity sufficient to effectively treat or prophylactically treat the patient.

Object of the invention is also a pharmaceutical composition comprising a suitable carrier and/or diluent and, as an active principle, a conjugate between a polymer and an antibody against $\text{TNF}\alpha$, preferably a monoclonal antibody against human $\text{TNF}\alpha$.

The conjugates of this invention can be formulated according to well known methods by including appropriate amounts of the conjugates with a pharmaceutically acceptable carrier and/or diluent.

The following are examples of possible formulations:

1. CONJUGATE PEG-mAb78 LYOPHILIZED FORMULATION CONTAINING:
(composition of the pre-lyophilization solution)

Active Drug	from about 0.05% to about 0.5% w/v
25 Bulking Agent*	from about 2.50% to about 5.0% w/v
Surface-Active Agent **	from about 0.0025% to about 0.025% w/v
pH-Adjusting Agent ***	q.s. to pH 6.5 - 7.

- 16 -

2. CONJUGATE PEG-mAb78 "READY-TO-USE" FORMULATION CONTAINING:

Active Drug from about 0.05% to about 0.5% w/v

Surface-Active Agent** from about 0.0025% to about 0.025%
w/v

5 pH-Adjusting Agent*** q.s. to pH 6.5 - 7

W.F.I g.s.

In order to make an isotonic aqueous solution, an external agent (e.g. sodium chloride, sorbitol or dextrose) may be added at its isotonic level.

10 * e.g.: Lactose or Mannitol;
 ** e.g.: Polysorbates or Poloxamer;
 *** e.g.: NaOH 0.01 N or HCl 0.01N

W.F.I means water for injections.

- 17 -

EXAMPLE 1**Preparation of antiidiotypic mAb2**

The antiidiotypic monoclonal antibody (mAb2) was generated as previously described (M. Monestier, Cancer Research 49 : 123-126, 1989). BALB/C mice were immunized two times by i.p. injection of 100 µg/mouse of purified BSA-mAb78 in Complete Freund's Adjuvant. Animals were boosted i.p. three times, every two weeks, with 100 µg/mouse of BSA-mAb78 in PBS.

10 The animals were sacrificed three days after the last immunization and their splenocytes fused with non-secreting murine myeloma NSO according to standard techniques (Galfre, C. Methods of Enzymology 73 : 3-46, 1981).

Culture supernatants from grown hybridomas were then
15 screened by ELISA for the presence of antiidiotypic antibodies.

Briefly, goat-anti-mouse Ig was diluted at 10 µg/ml in phosphate buffer pH 7.2 and added (100 µl/well) to a polyvinylchloride flat bottom-microtitration plate (Falcon
20 3912).

After overnight incubation at 4°C the plate was saturated with 100 µl/well of BSA (1% in PBS) for 3 hours at room temperature.

Culture supernatants, were added (50 µl/well) and
25 incubated 1 hour at 37°C.

After washing, the biotinylated mAb78 (0.25 µg/ml in PBS - 0.05% Tween - 1% BSA) was added and incubated for 1 hour at 37°C. After washing, avidin-peroxidase (Vector Laboratories,

- 18 -

Burlingame, CA) was added at 0.25 µg/ml in PBS-Tween-BSA for 1 hour at 37°C. After extensive washing, 100 µl of peroxidase substrate (OPD2, Chemicon, SCI. Rome, Italy, 1 Tablet in 5 ml of citrate buffer, OPD4, Chemicon), was added 5 to each well.

The reaction was stopped after 2 minutes with 100 µl/well of 4M H₂SO₄ and optical density was read at 492 nm.

One of the positive hybridomas, selected for the production of antiidiotypic monoclonal antibodies able to 10 interfere with the binding of mAb78 to huTNFα was cloned twice by limiting dilution.

The clone 65 producing the antiidiotypic monoclonal antibody (mAb2) was expanded, the mAb2 produced was purified from the supernatant and used to protect the binding side of 15 mAb78 to huTNFα in the experiments of Example 2 which follows.

- 19 -

EXAMPLE 2**1. METHODS****5 1. Derivatization of a mAb1 with mPEG according to the prior art.**

For this purpose 400 µg of mAb78 (EP-A-0492488; mAb1) were incubated for 30 minutes in 1 ml PBS (phosphate buffered saline) pH 7.2 in the absence or presence of
10 different molar excesses of mPEG (monomethoxy-polyethylene glycol succinimidyl succinate, Polymer Labs., Church Stretton, UK). mAb78 is a mAb against hu TNFα. In one instance a dose of mouse IgG equivalent to
15 that of antiidiotypic mAb2 employed in the protected derivatization (800 µg, see below) was added and the molar excess of mPEG was calculated on the concentration of mAb78 + mouse IgG. At the end of the incubation, bovine serum albumin (BSA, Armour, Kankakee, Illinois)
20 was added to a final concentration of 0.5% to quench free, unreacted mPEG.

2. Covalent coupling of a mAb2 to solid-phase.

25

For this purpose 5 mg of mAb2 were coupled to CNBr-activated Sepharose (Pharmacia LKB, Uppsala, Sweden) following the manufacturer's instructions.

- 20 -

3. Protected derivatization of mAb78 with mPEG.

5 Sephadex-bound mAb2 (800 µg) was incubated with 400 µg
mAb78 in 1 ml PBS pH 7.2 for 4 h under constant
agitation at room temperature. Then, after
centrifugation, the bead-pellet was resuspended for 30
minutes under the same conditions in 1 ml PBS pH 7.2
without or with different molar excesses of mPEG
10 (calculated on the mAb78 + mAb2 concentration).
Sephadex-bound mAb78/mAb2 complexes were then
centrifuged 4 times, then resuspended in glycine-HCl, pH
4 buffer, recentrifuged and resuspended for 5 min in
glycine-HCl, pH 2.8 buffer to elute mAb78. Upon a final
15 centrifugation supernatants were collected, adjusted to
neutral pH and eluted mAb78 was quantified by means of
a commercially available kit (Bio-Rad Micro-Assay,
Segrate, Italy) following the manufacturer's
instructions. Thereafter BSA was added to a final
20 concentration of 0.5% to quench free, unreacted mPEG.

4. Determination of the neutralizing activity of mAb78 or
mAb78-mPEG conjugates.

25 On day 0 logarithmically growing mouse IM cells (Rubin,
B.Y. et al, J. Exp. Med., 162 : 1099 (1985)) were
trypsinized, centrifuged and resuspended at a final
concentration of 3×10^5 cells/ml of Eagle's minimum

- 21 -

essential medium supplemented with 5% FCS and 2mM glutamine (complete MEM).

100 µl of this suspension were added to the wells of flat bottom microtiter plates (Falcon 3072). Then a dilution of
5 huTNF α (Esquire Chemie, Zuerich, Switzerland) was set up in complete MEM to have a final concentration, after addition to wells, of 1 ng/ml.

mAb78 or mAb78-mPEG conjugates were diluted in complete MEM and added to wells to have final concentrations from 200
10 ng/ml to 0.35 ng/ml.

50 µl of diluted huTNF α were then incubated with 50 µl of each mAb78 or mAb78-mPEG conjugate dilution or with 50 µl complete MEM for 2 hours at 37°C. During this incubation period a solution containing actinomycin D (Fluka, Buchs,
15 Switzerland) was set up in complete MEM.

The final concentration of actinomycin D after addition to the wells was 2 µg/ml. At the end of the incubation period each mAb78-huTNF α or mAb78-mPEG conjugate-huTNF α mixture and 50 µl of actinomycin D were added to the wells of microtiter
20 plates. To some wells 100 µl of huTNF α alone were added. To some controls wells only actinomycin D-solution and complete MEM were added. Thereafter the plates were incubated for 24 hours at 37°C.

After the incubation a fresh solution of MTT (CALBIOCHEM
25 589511 - La Jolla - CA) 5 mg/ml in PBS was prepared and 40 µl were transferred into each well. The plates were incubated at 37°C, 5% CO₂ for 4 hours. At the end of the incubation the medium was aspirated. DMSO (CARLO ERBA-ITALY) was then added

- 22 -

(200 μ l/well) and vigorously pipetted 2-3 times.

The plates were then read in the spectrophotometer at 570 nm wavelength.

5 The data were expressed in optical density (OD) UNITS. The OD values were expressed as percent values of those from the control wells (Actinomycin D alone).

10 These percent values were processed by means of the ELISA-Soft PC program (PERKIN-ELMER-NORWALK, CT USA) and the mAb78 concentration giving 50% cytotoxicity in the presence of 1 ng/ml huTNF α was thereby determined.

- 23 -

5. ELISA for the determination of mAb78 or mAb78-mPEG conjugates.

5 Flat-bottom microtiter plates were coated at 100 μ l/well with goat-anti mouse Ig (Biosys, Compiègne, France, 1 μ g/well) diluted in 40 mM phosphate buffer pH 7.4). After overnight incubation at 4°C, unabsorbed antibody was discarded and PBS pH 7.2, supplemented with 1% BSA, was added to each well to saturate unoccupied plastic sites.

10 The plates were further incubated for 3 hours at room temperature and thereafter washed 3 times with washing buffer (WB), that is PBS pH 7.2 supplemented with 0.1% Tween 20 (Merck, Schuchardt, Hohenbrunn, FRG) and 0.01% merthiolate (BDH, Pool, GB). During this incubation

15 period, serial two-fold dilutions of mAb78 or mPEG-mAb78 conjugates were set up. All dilutions were in PBS pH 7.2, 1% BSA. 50 μ l of each dilution were added to the wells, the plates incubated for 60' at 37°C and then washed as above. Then, 100 μ l of peroxidase-conjugated

20 goat anti-mouse IgG (Biosys, Compiègne, France) diluted 1:2000 in WB were added to each well, the plates incubated for 45 minutes at 37°C and washed as above. Then, 100 μ l of peroxidase substrate (OPD2, Chemicon, SCI, Rome, Italy, 1 tablet dissolved in 5 ml citrate

25 buffer, OPD4, Chemicon) were added to each well. The reaction was allowed to proceed for 2' at room temperature, after which color development was stopped by the addition of 100 μ l/well of 4 M H₂SO₄. The extent

- 24 -

of color development was read on a plate ELISA reader at 492 nm.

2. RESULTS

5

Derivatization of a mAb1 with mPEG according to the prior art.

In order to evaluate the effect of non-specific polymer-derivatization of a molecule (the conjugate being
10 prepared according to the prior art) on its biological activity, we chose as a model system a mAb1 against huTNF α . This mAb1 (mAb78; EP-A-0492488) neutralizes the cytotoxic activity of huTNF α on mouse LM cells. Thus, 1 ng/ml huTNF α kills 85-90% of LM cells in such a cytotoxicity assay. Upon
15 incubation of 1 ng/ml huTNF α with increasing concentrations of mAb78, a dose-dependent inhibition of the cytotoxic activity is observed (Fig. 1). In this assay, 1 ng/ml huTNF α exerted 50% cytotoxic activity in the presence of 6.7 ng/ml mAb78.

20

We then synthesised a conjugate of mAb78 with mPEG (prepared according to the prior art) using different molar ratios of mPEG/mAb78. Increasing concentrations of each mAb78-mPEG conjugate were incubated with 1 ng/ml huTNF α and the concentration of each conjugate at which 50% cytotoxicity
25 was observed was determined. As can be seen from Fig. 2, there was a correlation between the increase of the mAb78-mPEG concentration required to give 50% cytotoxicity and increasing molar ratios of mPEG/mAb78 conjugates. At the

- 25 -

highest ratio employed (500:1), 50% cytotoxicity was observed at a mAb78-mPEG concentration of 49 ng/ml. These results show that polymer-derivatization of mAb78 according to the prior art causes, at increasing molar ratios of mPEG/mAb78 employed
5 during the conjugation step, an increasing loss of biological activity. This is reflected in the increasing mAb78-mPEG concentrations required to reduce the cytotoxic activity of 1 ng/ml huTNF α from 85-90% to 50%.

10 Protected derivatization of a mAb1 with mPEG according to the present invention.

In order to perform the conjugation step under conditions whereby the antigen (huTNF α)-binding regions of
15 mAb78 are protected from polymer derivatization according to the present invention, we took advantage of an antiidiotypic mAb (mAb2) that interferes with the binding of mAb78 to huTNF α , and consequently with the neutralization of huTNF α by mAb78. This property assures that mAb2 shields, during the
20 conjugation process, the mAb78-domains involved in huTNF α -binding, thereby preserving the antigen (huTNF α)-binding and neutralizing activity of mAb78.

We therefore performed derivatization of mAb78 in the presence of protection afforded by mAb2 at mPEG/mAb78 +
25 mAb2 ratios of 15:1, 100:1, 500:1. Derivatized mAb78 was recovered upon elution with 0.1 M glycine-HCl pH-2.8. The results of the 3 experiments that have been performed are shown in Table 1 and Figure 3. In each experiment we included

- 26 -

as a control mock-derivatized mAb78, i.e. mAb78 that was submitted to the same procedure as the afore-mentioned samples but without adding mPEG. Still another control included in each experiment was mAb78 derivatized according to the prior art, i.e. without protection afforded by mAb2. A control included in experiment 2 was mAb78 derivatized without protection in the presence of mouse IgG at a concentration equivalent to that of mAb2 used for the protected derivatization.

10 The results show that when mAb78 was derivatized without protection afforded by mAb2, either in the presence or absence of mouse IgG, the expected decrease in neutralizing activity was observed. On the other hand, derivatization performed according to the present invention
15 allowed the recovery of mAb78-mPEG conjugates with fully preserved biological activity. These results show that polymer-derivatization of bioactive molecules according to the present invention, i.e. having the active domains protected through interaction with a specific binder, during
20 the conjugation step, allows indeed a full recovery of the desired biological activity(ies).

Recognition of protected and unprotected mAb78-mPEG
conjugates by anti-mouse IgG antibodies.

25

It is well known from the prior art that polymer-derivatized proteins, that are heterologous with respect to the species to be treated, are recognized much less

- 27 -

efficiently by antibodies produced upon administration of the underivatized protein (see, generally, Fuertges, F. and Abuchowski, A., Journal of Controlled Release, 11 : 139-148, 1990).

5 We therefore compared the reactivity of mAb78-mPEG conjugates, that had been generated without or with protection afforded by mAb2, with anti-mouse IgG antibodies in ELISA. Such antibodies react with antigenic determinants common to all mouse antibodies of IgG isotype and, therefore,
10 also with mAb78 which is an IgG1,k antibody. As can be seen from Fig. 4, the reactivity of the protected as well as that of the unprotected mAb78-mPEG conjugates was similarly decreased compared to unconjugated mAb78.

EXAMPLE 3

15 Methods

1. Derivatization of huTNF α with mPEG according to the prior art.

For this purpose 200 μ g of recombinant human TNF- α (WOC Ltd. Vaduz, Luxemburg; specific activity: 3.2×10^7 units/mg; purity: >97%) were incubated for 3 h in 0.2 ml, 25 mM sodium
20 borate buffer, pH 8.0, in the absence or presence of different molar excesses of mPEG (Methoxypolyethylene glycol-Cyanuric chloride; Sigma M3277, Milano, Italy). At the end of the incubation, mPEG excess removed by gel filtration on a
25 Sephacryl S200 column (Pharmacia, Uppsala, Sweden) equilibrated with PBS, pH 7.2. Protein concentration was quantified by means of commercially available kit (Bio-Rad Micro-assay, Segrate, Italy) following the manufacturer's

- 28 -

instructions.

2. Covalent coupling of mAb 78 to solid-phase.

For this purpose, 2 mg of mAb 78 were coupled to 1 ml AFFI-
gel 10 (Bio-Rad, Segrate, Italy) following the manufacturer's
5 instructions.

3. Protected derivatization of huTNF α with mPEG.

Sepharose-bound mAb 78 (400 μ g) was incubated with 100 μ g
huTNF α in 1 ml PBS pH 7.2 for 4 h under constant rotation at
room temperature. Then, after centrifugation and washings,
10 the bead-pellet was resuspended for 3 h under the same
conditions in 25 mM sodium borate buffer, pH 8.0, and
different molar excesses of mPEG were added (calculated on
the mAb 78 + huTNF α concentration). The Sepharose bound huTNF
 α /mAb78 complex was washed 4 times, then resuspended in
15 universal buffer (6.7 mM citric acid, 6.7 mM orthophosphoric
acid, 11.4 mM orthoboric acid), pH 3.0 to elute huTNF α . After
a final centrifugation, supernatants were collected, adjusted
to neutral pH and eluted huTNF α was quantified by means of
commercially available kit (Bio-Rad Micro-assay, Segrate,
20 Italy) following the manufacturer's instructions. mPEG
incorporation was assessed by means of HPLC analysis, on a
Superose 6 HR 10/30 column (Pharmacia, Uppsala, Sweden)
equilibrated with 0.1 M sodium phosphate buffer, pH 7.0, as
molecular weight increase in comparison with the native
25 protein. The column was calibrated using commercially
available molecular weight standards (Bio-Rad cat.151-1901;
Milan, Italy).

- 29 -

4. Cloning and expression of the extracellular domain of 55kDa human TNF receptor.

Human recombinant TNF α receptor, extracellular portion of the p55 receptor, linked to a poly-histidine codon, molecular weight 19 Kd; was cloned, produced and purified to homogeneity (over 95% as determined by SDS-PAGE) by Farmitalia Carlo Erba, Milan Italy according to the procedure described by Fountoulakis M. et al, 1990, J.B.C. 265, 13268-13275.

The cDNA for the 55kDa human TNF receptor, was isolated by screening a λ gt11 library (Clontech) using as probe two synthetic oligonucleotides designed according to the published nucleotide sequence of the 55kDa receptor (Gray et al. 1990 PNAS USA 87, 7380-7837).

The cDNA coding the extracellular domain of 55kDa TNFR was cloned in a plasmid of the pQE series type IV (DIAGEN GmbH - Hilden- Germany) fused in frame to a polyHis tail.

The insertion of the cDNA was carried out following amplification by Polymerase Chain Reaction (PCR); PCR primers were selected to introduce restriction sites compatible with the sites present in the pQE9 polylinker; in addition a translation stop codon was engineered behind the nucleotides corresponding to the last aminoacid of the extracellular domain. The plasmid, called pFC228, was transformed in a K12 derived E.coli strains: M15(pREP4).

The new strain was called FICE 284.

5. Radioimmunoassay for the determination of the binding of TNF α -mPEG conjugates to insolubilized recombinant TNF-R1 receptor.

Round bottom microtiter plates were coated with 0.1 ml of recombinant external domain of the TNF-R1 receptor as obtained from FICE 284 (120 ng/well in 0.1 M carbonate buffer, pH 9.6). After an overnight incubation at 4°C, plates

- 30 -

5 were washed three times with WB, overcoated with 1% BSA for 1 h at room temperature and washed as before. Plates were then added with 50 μ l of 125 I-huTNF α (specific activity: 40.3 μ Ci/ μ g; NEN Dreieich, W. Germany) plus 50 μ l of serial two-fold dilutions of huTNF α , unprotected huTNF α -mPEG or huTNF α -mPEG protected by insolubilized mAb 78. Following a 2 h incubation, plates were washed three time with WB and the radioactivity present in each well was measured in a gamma counter.

10 Results

Derivatization of human TNF- α with mPEG according to the prior art.

15 In order to evaluate the effect of non-specific polymer-derivatization on huTNF α , we prepared a series of conjugates of huTNF α with 10, 20 and 30 molar excesses of mPEG and tested them in a cytotoxicity assay and in a binding assay to huTNF α receptor. The cytotoxic activity of the native and derivatized huTNF α was determined using mouse LM cells. Derivatized huTNF α displayed a substantial dose-dependent
20 decrease of cytotoxicity with respect to the native protein (Table 2). When tested in a binding assay, all conjugates showed a substantial loss of their ability to displace the binding of 125 I-huTNF α from insolubilized human TNF α receptor (Fig. 5). Loss of binding of mPEG-huTNF α to the receptor was
25 evident even when the conjugates where tested at concentrations 100 fold higher with respect to the amount of native molecule able to displace 50% of the radioactivity.

Protected derivatization of huTNF α with mPEG according to the present invention.

30 In order to evaluate the effect of protection by a monoclonal antibody on the binding site of huTNF α to its

- 31 -

specific receptor, we prepared a series of conjugates between huTNF α and mPEG at 10 and 30 fold molar excesses (calculated on the mAb 78 + huTNF α concentration) after binding huTNF α to insolubilized mAb 78. The latter monoclonal antibody, being
5 able to neutralize the cytotoxic activity of the huTNF α , probably recognizes an epitope involved in the recognition of the cytokine by its receptor. After derivatization, products were analyzed by HPLC. Both the protected and unprotected conjugates displayed a molecular weight substantially higher
10 (128 Kd) than the native TNF- α (34 Kd). The cytotoxic activity of the protected derivatized huTNF α was determined using mouse LM cells. The protected conjugates displayed a better retention of biological activity in comparison with the analogous unprotected conjugates (Table 2). Moreover, the
15 protected conjugates were able to displace the binding of 125 I-huTNF α to insolubilized recombinant human TNF α receptor at concentration significantly lower than the analogous unprotected conjugates (Fig. 5).

It can be therefore concluded that polymer-
20 derivatization of bioactive molecules according to the present invention, whereby the domain(s) mediating the desired biological activity(ies) are protected through interaction with a specific binder, results in a greatly decreased reactivity with antibodies raised against the
25 underivatized molecule, a decrease similar to that observed upon derivatization performed according to the prior art. In the latter case, however, this is obtained at the expense of a significant loss of the desired biological activity, whereas for conjugates obtained according to the present
30 invention, the biological activity is preserved.

- 32 -

TABLE 1

Concentrations of mAb78, unprotected mAb78-mPEG conjugates or protected mAb78-mPEG conjugates at which 1 ng/ml huTNF α exerts 50% cytotoxic activity on IM cells.

		Concentration (ng/ml)
5	mAb78 ^a	6.7
	Unprotected mAb78+mPEG 15x ^b	23.6
	Unprotected mAb78+mPEG 100x	41.61
	10 1.Experiment Unprotected mAb78+mouse IgG	
	+mPEG 100x ^c	37.32
15	Protected mAb78+mPEG 15x ^d	7.0
	Protected mAb78+mPEG 100x	7.16
	2.Experiment mAb78	6.93
	Unprotected mAb78+mPEG 100x	39.06
	Protected mAb78+mPEG 100x	7.06
20	mAb78	7.2
	3.Experiment Unprotected mAb78+mPEG 500x	49.0
	Protected mAb78+mPEG 500x	7.8

^a Mock-derivatized mAb78

25 ^b Unprotected mAb78 derivatized upon addition of a 15-fold molar excess of mPEG (calculated on the mAb78 concentration)

- 33 -

- ^c Unprotected mAb78 and mouse IgG derivatized upon addition of a 100-fold molar excess of mPEG (calculated on the mAb78 + mouse IgG concentration)
- 5 ^d Protected mAb78 derivatized upon addition of a 15-fold molar excess of mPEG (calculated on the concentration of mAb78 and that of the specific binder mAb2).

- 34 -

TABLE 2 - Doses of protected and unprotected TNF α -mPEG giving 50% of cytotoxicity on LM cells.

mPEG (cyanuric - chloride)	huTNF α - mPEG	Protected huTNF α -mPEG
0	0.03 ng/ml	0.03 ng/ml
10x	1.09 ng/ml	0.14 ng/ml
20x	3.90 ng/ml	-
30x	5.40 ng/ml	0.25 ng/ml

- 35 -

CLAIMS

1. A process for the preparation of a conjugate between a polymer and a first substance having a biological activity mediated by a domain thereof, which process
5 comprises:

(a) contacting the first substance with a second substance which specifically binds to the said domain of the first substance;

(b) conjugating a polymer to the first substance
10 having the second substance bound thereof; and

(c) freeing the second substance from the first substance having the polymer conjugated thereto and wherein, when the first substance is a proteolytic enzyme chosen from trypsin, urokinase, tissue plasminogen activator, plasmin,
15 chymotrypsin, elastase and kallikrein then the polymer is other than polyethylene glycol.

2. A process according to claim 1, wherein the first substance is a protein or glycoprotein.

3. A process according to claim 2, wherein the
20 first substance is a monoclonal antibody or fragment thereof and the second substance is an antiidiotype antibody or the antigen to which the monoclonal antibody or fragment thereof binds.

4. A process according to claim 3, wherein the
25 first substance is a non-human monoclonal antibody specific for human TNF α and the second substance is a corresponding antiidiotype antibody.

5. A process according to claim 2, wherein the
30 first substance is TNF α and the second substance is an antibody to which TNF α binds.

6. A process according to claim 5, wherein the first substance is human TNF α and the second substance is a corresponding non-human monoclonal antibody.

7. A process according to any one of the preceding
35 claims, wherein the polymer, which is conjugated to the first

- 36 -

substance having the second substance bound thereto, is a poly(ethylene glycol) or N-(2-hydroxypropyl)-methacrylamide polymer.

8. A conjugate between a polymer and an antibody
5 against TNF- α .

9. A conjugate according to claim 8, wherein the antibody is a monoclonal antibody against human TNF α .

10. A conjugate according to claim 8, wherein the polymer is an inert, synthetic, water soluble polymeric
10 carrier.



11. A conjugate according to claim 8, wherein the polymer is chosen from poly(ethylene glycol) (PEG), poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(amino acids), divinylether maleic anhydride, ethylene-maleic
15 anhydride, N-(2-hydroxypropyl)-methacrylamide and dextran polymers.

12. A conjugate according to claim 9, wherein the antibody is mAb78.



13. A pharmaceutical composition comprising a
20 pharmaceutically acceptable carrier and/or diluent and, as an active principle a conjugate between a polymer and an antibody against TNF- α .

14. A conjugate according to claim 8 for use as a prophylactic or therapeutic agent in a disease state in which
25 human TNF- α exerts a pathogenic effect.


1/3

Fig.1.*Fig.2.*


2/3

Fig.3.*Fig.5.*

3/3

A.
Fig.4.

B.



INTERNATIONAL SEARCH REPORT

Int. National Application No

PCT/EP 93/03429

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP,A,0 568 500 (MINISTERO DELL' UNIVESITA'E DELLA RICERCA SCIENTIFCA E TECNOLOGICA)	8-14
Y	see page 3, line 28 - line 39; claims ---	1-14
X,Y	CHEMICAL ABSTRACTS, vol. 114, no. 3, 21 January 1991, Columbus, Ohio, US; abstract no. 20654s, see abstract & JP,A,2 201 162 (TEIJIN LTD) 9 August 1990 see the whole document ----- -/-	1-14

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

6 April 1994

Date of mailing of the international search report

20. 04. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/EP 93/03429

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 111, no. 5, 31 July 1989, Columbus, Ohio, US; abstract no. 37512e, see abstract & CLIN. CHIM. ACTA, vol.181, no.2, 1989 pages 223 - 229 ABE YASUHI TO ET AL. 'NONSPECIFIC REACTION IN THE SANDWICH IMMUNOASSAY FOR HUMAN NECROSIS FACTOR-ALPHA' see the whole document ----	1-14
P,X	MOLECULAR IMMUNOLOGY, vol.30, no.12, August 1993 pages 1123 - 1131 A. CORTI 'EVIDENCES THAT SYNGENEIC ALPHA-TYPE ANTI-IDIOTYPIC ANTIBODIES MAY NON-COMPETITIVELY INHIBIT IDIOTYPE/OLIGOMERIC ANTIGEN INTERACTIONS BY AFFECTING IDIOTYPE AVIDITY.' see the whole document ---	8-14
P,A	HYBRIDOMA, vol.12, no.1, February 1993 pages 1 - 13 E. BARBANTI ET AL. 'MODE OF INTERACTION BETWEEN TUMOR NECROSIS FACTOR AND A mOAB EXPRESSING A RECURRENT IDIOTYPE' see page 2; examples -----	1-14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 93/03429

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-14
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
In view of the definition of products by means of their biological, chemical and or pharmacological properties, the search has to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims or examples.
3. ☐ Claims Nos.: (see guidelines, Part B, Chapter III, paragraph 3.6)
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). PCT.

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 93/03429

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0568500	03-11-93	NONE	
JP-A-2201162	09-08-90	NONE	

1. The first part of the document is a list of names and addresses of the members of the committee.